Literature DB >> 17575142

c-FLIP: a key regulator of colorectal cancer cell death.

Timothy R Wilson1, Kirsty M McLaughlin, Miranda McEwan, Hidekazu Sakai, Katherine M A Rogers, Kelly M Redmond, Patrick G Johnston, Daniel B Longley.   

Abstract

c-FLIP is an inhibitor of apoptosis mediated by the death receptors Fas, DR4, and DR5 and is expressed as long (c-FLIP(L)) and short (c-FLIP(S)) splice forms. We found that small interfering RNA (siRNA)-mediated silencing of c-FLIP induced spontaneous apoptosis in a panel of p53 wild-type, mutant, and null colorectal cancer cell lines and that this apoptosis was mediated by caspase-8 and Fas-associated death domain. Further analyses indicated the involvement of DR5 and/or Fas (but not DR4) in regulating apoptosis induced by c-FLIP siRNA. Interestingly, these effects were not dependent on activation of DR5 or Fas by their ligands tumor necrosis factor-related apoptosis-inducing ligand and FasL. Overexpression of c-FLIP(L), but not c-FLIP(S), significantly decreased spontaneous and chemotherapy-induced apoptosis in HCT116 cells. Further analyses with splice form-specific siRNAs indicated that c-FLIP(L) was the more important splice form in regulating apoptosis in HCT116, H630, and LoVo cells, although specific knockdown of c-FLIP(S) induced more apoptosis in the HT29 cell line. Importantly, intratumoral delivery of c-FLIP-targeted siRNA duplexes induced apoptosis and inhibited the growth of HCT116 xenografts in BALB/c severe combined immunodeficient mice. In addition, the growth of c-FLIP(L)-overexpressing colorectal cancer xenografts was more rapid than control xenografts, an effect that was significantly enhanced in the presence of chemotherapy. These results indicate that c-FLIP inhibits spontaneous death ligand-independent, death receptor-mediated apoptosis in colorectal cancer cells and that targeting c-FLIP may have therapeutic potential for the treatment of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17575142     DOI: 10.1158/0008-5472.CAN-06-3585

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  57 in total

1.  4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide (CMH) targets mRNA of the c-FLIP variants and induces apoptosis in MCF-7 human breast cancer cells.

Authors:  Khadijeh Bijangi-Vishehsaraei; Mohammad Reza Saadatzadeh; Su Huang; Ahmad R Safa; Michael P Murphy
Journal:  Mol Cell Biochem       Date:  2010-05-06       Impact factor: 3.396

2.  Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.

Authors:  A Morizot; D Mérino; N Lalaoui; G Jacquemin; V Granci; E Iessi; D Lanneau; F Bouyer; E Solary; B Chauffert; P Saas; C Garrido; O Micheau
Journal:  Cell Death Differ       Date:  2010-11-12       Impact factor: 15.828

3.  Regulation of colorectal cancer cell apoptosis by the n-3 polyunsaturated fatty acids Docosahexaenoic and Eicosapentaenoic.

Authors:  Anna Giros; Mike Grzybowski; Vanessa R Sohn; Elisenda Pons; Jessica Fernandez-Morales; Rosa M Xicola; Puja Sethi; Jessica Grzybowski; Ajay Goel; C Richard Boland; Miquel A Gassull; Xavier Llor
Journal:  Cancer Prev Res (Phila)       Date:  2009-07-28

4.  HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.

Authors:  Robbie Carson; Basak Celtikci; Patrick G Johnston; Sandra Van Schaeybroeck; Cathy Fenning; Arman Javadi; Nyree Crawford; Lucia Perez Carbonell; Mark Lawler; Daniel B Longley
Journal:  Clin Cancer Res       Date:  2015-03-26       Impact factor: 12.531

5.  Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.

Authors:  Clare McCourt; Pamela Maxwell; Roberta Mazzucchelli; Rodolfo Montironi; Marina Scarpelli; Manuel Salto-Tellez; Joe M O'Sullivan; Daniel B Longley; David J J Waugh
Journal:  Clin Cancer Res       Date:  2012-05-23       Impact factor: 12.531

6.  Proteasomal regulation of caspase-8 in cancer cell apoptosis.

Authors:  Michael V Fiandalo; Steven R Schwarze; Natasha Kyprianou
Journal:  Apoptosis       Date:  2013-06       Impact factor: 4.677

Review 7.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.

Authors:  Ahmad R Safa; Travis W Day; Ching-Huang Wu
Journal:  Curr Cancer Drug Targets       Date:  2008-02       Impact factor: 3.428

8.  Basal cancer cell survival involves JNK2 suppression of a novel JNK1/c-Jun/Bcl-3 apoptotic network.

Authors:  Shafiq Uddin Ahmed; Jo Milner
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

9.  TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.

Authors:  Josep Maria Lluis; Ulrich Nachbur; Wendy Diane Cook; Ian Edward Gentle; Donia Moujalled; Maryline Moulin; Wendy Wei-Lynn Wong; Nufail Khan; Diep Chau; Bernard Andrew Callus; James Edward Vince; John Silke; David Lawrence Vaux
Journal:  PLoS One       Date:  2010-01-08       Impact factor: 3.240

10.  Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.

Authors:  T Trarbach; M Moehler; V Heinemann; C-H Köhne; M Przyborek; C Schulz; V Sneller; G Gallant; S Kanzler
Journal:  Br J Cancer       Date:  2010-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.